Compare Banco Santander SA (SAN) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Santander SA vs Travere Therapeutics Inc. Common Stock — how do they compare? Banco Santander SA trades at $13.38 (market cap $196.48B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Banco Santander SA is far larger — about 40.3× Travere Therapeutics Inc. Common Stock's market cap, and Banco Santander SA pays a 2.14% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Banco Santander SA for 55 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SAN | TVTX | |
|---|---|---|
Market Cap | $196.48B | $4.88B |
Volume | 9,811,951 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $15.05 | $67.52 |
52-Week Low | $9.65 | $26.79 |
Typical Hold Time | 55 Days | 0 Days |
Enterprise Value | $362.68B | $5.01B |
Dividend Yield | 2.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Banco Santander (SAN) trades at $13.41, down 0.52% on the day, with a bearish technical signal from moving averages and a mixed earnings history including a Q1 2026 beat. The company maintains strong profitability with a 26.25% net income margin and a 16.07% ROE, supported by record profits highlighted in recent earnings calls. Recent developments include the completion of the Webster acquisition, expanding its U.S. presence, and a dividend payment scheduled for November 2026.
The outlook is cautiously optimistic with analyst consensus at 'Moderate Buy' (64% buy ratings), but risks include declining cash flows from operations and rising debt-to-asset ratios. Revenue growth is projected to reach $61.9B in 2026, though net cash flow turned negative in 2024-2025, signaling potential liquidity pressures. Investors should weigh strong profitability against financial leverage and integration risks from acquisitions.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
